Legal Action Emerges for Investors in PROCEPT BioRobotics Corporation Amid Allegations of Securities Fraud
In a significant development for investors of PROCEPT BioRobotics Corporation, a class action lawsuit has been initiated due to allegations of securities fraud. The law firm Hagens Berman Sobol Shapiro LLP is leading a legal inquiry into the claims that the company misrepresented sales performance of its surgical devices, specifically focusing on the single-use handpiece used in its innovative Aquablation therapy designed for treating enlarged prostates. This lawsuit comes in light of considerable and unexpected declines in product sales, coupled with revelations regarding inflated inventory practices.
The lawsuit encompasses a class period from February 28, 2024, to February 25, 2026, targeting those who purchased PROCEPT stock during this timeframe. Investors are encouraged to come forward if they experienced substantial financial losses as a result of the alleged fraudulent activities. According to the suit, PROCEPT's executives purportedly misled the market regarding the sales trends of their product, contrary to the realities that surfaced subsequently.
Specifically, the complaint highlights that the company used aggressive discounting strategies to boost immediate sales figures, which were artificially inflated by pushing customers to place bulk orders that exceeded their actual needs. This led to a scenario where sales growth would appear strong on paper, while underlying demand was considerably weaker than portrayed. By encouraging bulk purchases, PROCEPT effectively 'pulled forward' sales from future periods, a tactic that benefitted short-term visibility at the expense of long-term stability.
The truth about these operational strategies began to unfold gradually. On August 6, 2025, PROCEPT released its Q2 financial results, missing sales expectations by a notable margin. The situation continued to deteriorate when, in November 2025, the company reported Q3 results that once again fell short, leading to a drastic reduction in their annual sales guidance during the subsequent earnings call. Investors were informed that inventories were being mismanaged and many customers had accumulated excessive stocks of handpieces, leading to a significant drop in sales figures.
By February 25, 2026, a shocking Q4 report revealed that the company disclosed actual sales figures which showed persistent overstock issues, with customer inventories exceeding 10,000 units. U.S. sales of handpieces dropped sharply by 30%, contradicting prior claims from management regarding their operations. In light of these revelations, PROCEPT announced the termination of its secretive bulk order discount program, which many believe contributed to the misleading sales figures.
Lead attorney Reed Kathrein emphasized the urgency of the inquiry, stating:
Such claims suggest a serious breach of fiduciary duty and a violation of federal securities laws concerning accurate reporting and investor communication.
Investors who believe they have suffered losses related to these developments are urged to contact Hagens Berman as the investigation continues. Individuals with non-public information that may assist in this case are also encouraged to reach out or consider participating in the SEC Whistleblower Program, which offers financial incentives for information leading to successful recovery efforts.
Hagens Berman has historically played a crucial role in corporate accountability within the financial sector, securing over $2.9 billion on behalf of investors affected by corporate malpractice. The firm remains committed to representing those harmed by the alleged fraudulent actions of PROCEPT BioRobotics.
For further updates and insights, those interested can follow the investigation via Hagens Berman’s social media or their official website. This development serves as a crucial reminder about the importance of transparency and honesty in corporate communications, particularly when it comes to investor relations and securities markets.
Background of the Allegations
The lawsuit encompasses a class period from February 28, 2024, to February 25, 2026, targeting those who purchased PROCEPT stock during this timeframe. Investors are encouraged to come forward if they experienced substantial financial losses as a result of the alleged fraudulent activities. According to the suit, PROCEPT's executives purportedly misled the market regarding the sales trends of their product, contrary to the realities that surfaced subsequently.
Specifically, the complaint highlights that the company used aggressive discounting strategies to boost immediate sales figures, which were artificially inflated by pushing customers to place bulk orders that exceeded their actual needs. This led to a scenario where sales growth would appear strong on paper, while underlying demand was considerably weaker than portrayed. By encouraging bulk purchases, PROCEPT effectively 'pulled forward' sales from future periods, a tactic that benefitted short-term visibility at the expense of long-term stability.
Events Leading to the Lawsuit
The truth about these operational strategies began to unfold gradually. On August 6, 2025, PROCEPT released its Q2 financial results, missing sales expectations by a notable margin. The situation continued to deteriorate when, in November 2025, the company reported Q3 results that once again fell short, leading to a drastic reduction in their annual sales guidance during the subsequent earnings call. Investors were informed that inventories were being mismanaged and many customers had accumulated excessive stocks of handpieces, leading to a significant drop in sales figures.
By February 25, 2026, a shocking Q4 report revealed that the company disclosed actual sales figures which showed persistent overstock issues, with customer inventories exceeding 10,000 units. U.S. sales of handpieces dropped sharply by 30%, contradicting prior claims from management regarding their operations. In light of these revelations, PROCEPT announced the termination of its secretive bulk order discount program, which many believe contributed to the misleading sales figures.
Continuation of Investigation
Lead attorney Reed Kathrein emphasized the urgency of the inquiry, stating:
"We’re focused on whether PROCEPT may have intentionally pulled in sales from future quarters to project an image of meeting expectations, and if the company had been transparent enough in its communications with investors."
Such claims suggest a serious breach of fiduciary duty and a violation of federal securities laws concerning accurate reporting and investor communication.
Seeking Investor Participation
Investors who believe they have suffered losses related to these developments are urged to contact Hagens Berman as the investigation continues. Individuals with non-public information that may assist in this case are also encouraged to reach out or consider participating in the SEC Whistleblower Program, which offers financial incentives for information leading to successful recovery efforts.
Hagens Berman has historically played a crucial role in corporate accountability within the financial sector, securing over $2.9 billion on behalf of investors affected by corporate malpractice. The firm remains committed to representing those harmed by the alleged fraudulent actions of PROCEPT BioRobotics.
For further updates and insights, those interested can follow the investigation via Hagens Berman’s social media or their official website. This development serves as a crucial reminder about the importance of transparency and honesty in corporate communications, particularly when it comes to investor relations and securities markets.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.